3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML

Leukemia. 2000 Feb;14(2):340-2. doi: 10.1038/sj.leu.2401670.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / adverse effects
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Female
  • Germany
  • Humans
  • Idarubicin / administration & dosage*
  • Idarubicin / adverse effects
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Pilot Projects
  • Remission Induction
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Idarubicin